Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events ‐ Gastrointestinal disturbances · women with subfertility
The review found no eligible studies for this question.
1 finding from 1 review
Anxiety (adverse effect, post‐intervention) · schizophrenia or related disorders
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events № of participants: 656 (2 RCTs) · Bell's palsy
It is very uncertain whether antivirals plus corticosteroids changes adverse events № of participants: 656 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (very low certainty).
1 finding from 1 review
RR 1.17 [0.81, 1.68]
Studies not reported
Very low
Adverse events (machine tolerability outcomes) · adults with a diagnosis of sleep apnoea
1 finding from 1 review
Adverse events (machine tolerability outcomes) · adults with a diagnosis of sleep apnoea
1 finding from 1 review
Adverse events (machine tolerability outcomes) · adults with a diagnosis of OSA
1 finding from 1 review
Discontinuation of medication due to adverse events · Women of reproductive age seeking to avoid pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events measured during study treatment · clinical diagnosis of depression
Acupuncture showed no clear difference in adverse events measured during study treatment compared with psychological therapy (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Two infusions of natalizumab (6 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants reporting an adverse event · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants reporting an adverse event · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants reporting an adverse event · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants reporting an adverse event · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review